外科手术中的基因治疗：第二部分：在感染性休克和器官移植中的应用。
Gene therapy in surgery: Part II: Application to septic shock and to organ transplantation.
作者信息
Rogy M A, Baumhofer Julie M, Beinhauer Britta, Brandmeier H, Eisenburger P, Losert U M, Philip Ramila
机构信息
1Division of General Surgery, Department of Surgery, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna.
2Center of Biomedical Research, University of Vienna, Austria.
出版信息
Acta Chir Austriaca. 1997;29(1):22-26. doi: 10.1007/BF02620270.
BACKGROUND
With the increasing body of knowledge in molecular biology, gene transfer respectively gene therapy becomes more and more a valid therapeutic option.
METHODS
This is a critical review of gene therapy protocols for treatment of different types of cancer. Furthermore, the pathophysiological mechanism, therapeutically strategies as well as experimental approaches toward gene transfer in septic shock and organ transplantation are critically elucidated.
RESULTS
Gene transfer as a therapeutic option was first successfully applied in children with severe combined immunodeficiency (SCID) in 1990. The majority of gene marking or gene therapy protocols approved for human clinical trials to date are related to the treatment of cancer. Besides viral vectors for brain tumors, non-viral vectors, liposomes particularly, with almost no side effects are increasingly used.
CONCLUSIONS
Different approaches of gene transfer in cancer patients are under investigation. Experimental data of septic shock treatment and rejection therapy of the allograft in organ recipients with gene transfer are encouraging for future applications in clinical trials.
背景
随着分子生物学知识体系的不断扩充，基因转移及基因治疗越来越成为一种有效的治疗选择。
方法
本文对治疗不同类型癌症的基因治疗方案进行了批判性综述。此外，还对脓毒症休克和器官移植中基因转移的病理生理机制、治疗策略及实验方法进行了批判性阐释。
结果
1990年，基因转移作为一种治疗选择首次在重症联合免疫缺陷（SCID）患儿中成功应用。迄今为止，大多数获批用于人体临床试验的基因标记或基因治疗方案都与癌症治疗有关。除了用于脑肿瘤的病毒载体外，几乎没有副作用的非病毒载体，尤其是脂质体，正越来越多地被使用。
结论
目前正在研究癌症患者中不同的基因转移方法。基因转移用于脓毒症休克治疗及器官移植受者同种异体移植物排斥治疗的实验数据，为其未来在临床试验中的应用带来了希望。
Zotero 插件